Abstract 09: Cancers with NTRK gene fusions: Molecular characteristics and prognosis

Volume: 26, Pages: 09 - 09
Published: Jun 15, 2020
Abstract
Introduction: The neurotrophic tyrosine receptor kinase (NTRK) genes NTRK1, 2, and 3 have emerged as oncogenic drivers, and their resultant tropomyosin receptor kinase (TRK) proteins are targets for precision medicines. Larotrectinib, a selective TRK inhibitor, and entrectinib, a multikinase inhibitor, have been approved for patients (pts) with TRK fusion cancer. This study was conducted to evaluate the molecular characteristics and prognosis of...
Paper Details
Title
Abstract 09: Cancers with NTRK gene fusions: Molecular characteristics and prognosis
Published Date
Jun 15, 2020
Volume
26
Pages
09 - 09
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.